+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Minimal detection bias in the inverse association between statin drug use and advanced prostate cancer risk: a simulation study



Minimal detection bias in the inverse association between statin drug use and advanced prostate cancer risk: a simulation study



Cancer Epidemiology 35(4): E6-11



Prospective studies support that statins may protect against advanced prostate cancer. Detection bias arising from higher PSA screening rates among statin users vs. non-users could produce an inverse association for advanced disease. Thus, we conducted simulations to assess whether this source of bias is explanatory. 3000 datasets with 100,000 men without prostate cancer were simulated for populations with high (65%) or low (15%) PSA screening. We investigated three scenarios: RR(true)=1.0, 0.75, and 0.5 for statins and advanced disease (1.0 for localized). We set the statin prevalence to 10% and varied the percentage of users who were PSA screened (0-100%). We assumed an annual total prostate cancer incidence of 1%, with risk in screened men twice that of unscreened men, and an advanced stage at diagnosis in 20% and 40% of cases in screened and unscreened men, respectively. As PSA screening and statin use became more coincident, the RR(observed) for local and total prostate cancer was biased upward from the RR(true) of 1.0, especially when the prevalence of PSA screening was low. However, in all simulated scenarios, there was little downward bias for advanced disease (e.g., if RR(true)=1.0 and 70% of statin users and either 65% or 15% of the population overall was PSA screened, then RR(observed)=0.98 for both). Given our assumptions, this simulation suggests that this source of detection bias is unlikely to explain the reported inverse association between statins and advanced prostate cancer, but may explain the positive association for total prostate cancer that has been reported in some studies.

(PDF emailed within 0-6 h: $19.90)

Accession: 054392386

Download citation: RISBibTeXText

PMID: 21167804

DOI: 10.1016/j.canep.2010.11.005


Related references

The association between metabolic syndrome and the risk of prostate cancer, high-grade prostate cancer, advanced prostate cancer, prostate cancer-specific mortality and biochemical recurrence. Journal of Experimental & Clinical Cancer Research 32: 9-9, 2013

Statin drugs and risk of advanced prostate cancer. Journal of the National Cancer Institute 98(24): 1819-1825, 2006

Re: Statin drugs and risk of advanced prostate cancer (PC) - Platz. 2007

Words of wisdom. Re: Statin drugs and risk of advanced prostate cancer (PC). European Urology 52(4): 1258-1259, 2007

Inverse association between prostatic polyunsaturated fatty acid and risk of locally advanced prostate carcinoma. Cancer 101(12): 2744-2754, 2004

Analysis of repeated 24-core saturation prostate biopsy: Inverse association between asymptomatic histological inflammation and prostate cancer detection. Oncology Letters 12(2): 1132-1138, 2016

Statin drug use is not associated with prostate cancer risk in men who are regularly screened. Journal of Urology 192(2): 379-384, 2014

Re: Statin drugs and risk of advanced prostate cancer (PC) - Platz Ea, Leitzmann MF, Visvanathan K, Rimm EB, Stampfer MJ, Willett WC, Giovannucci E J Natl Cancer Inst 2006;98 : 1819-25. 2007

A prospective study of joint association of IGF-I and dairy calcium intake with risk of advanced prostate cancer. Proceedings of the American Association for Cancer Research Annual Meeting 44: 719-720, July, 2003

Association of type 2 diabetes susceptibility variants with advanced prostate cancer risk in the Breast and Prostate Cancer Cohort Consortium. American Journal of Epidemiology 176(12): 1121-1129, 2013

Association of statin and nonsteroidal anti-inflammatory drug use with prostate cancer outcomes: results from CaPSURE. Bju International 106(5): 627-632, 2010

Role of serum cholesterol and statin use in the risk of prostate cancer detection and tumor aggressiveness. International Journal of Molecular Sciences 15(8): 13615-13623, 2015

Prostate cancer detection in prostate specific antigen range 20-39 ng/ml A study without verification bias. Journal of Urology 171(4 Supplement): 475, April, 2004

A population-based study of cancer incidence in relatives of prostate cancer patients in Finland High risk of late-onset prostate cancer and association with stomach cancer. American Journal of Human Genetics 65(4): A40, 1999

Statin use and risk of prostate cancer in the California Men's Health Study cohort. Cancer Epidemiology, Biomarkers & Prevention 16(11): 2218-2225, 2007